Weekly Update #11 - Week Ending 04/19/26

Key Takeaways

• Medexus now in 56 US transplant centers, 31% formulary coverage
• GRAFAPEX aims for >$100M peak annual revenue within five years
• PPIH Q4 sales hit $55.1M, EPS $0.60, beating estimates
• New Ohio AI data‑center facility could unlock large hyperscaler contracts
• Analysts may undervalue PPIH’s growth, missing $54M Q1 order boost

Pulse Analysis

Medexus Pharmaceuticals is gaining traction in the niche transplant market as its GRAFAPEX formulation reaches 56 U.S. centers, representing roughly one‑third of potential adopters. The drug’s inclusion on formularies signals clinician confidence and paves the way for the company’s ambitious $100 million peak‑revenue target within five years. At current pricing, that revenue horizon would compress the stock’s forward price‑to‑earnings multiple to about ten times, a valuation that appears attractive relative to peers in specialty oncology and transplant therapeutics.

Perma‑Pipe International Holdings (PPIH) delivered a robust fourth‑quarter performance, with sales climbing to $55.1 million and earnings per share surging to $0.60, well above consensus. The standout development is the launch of an Ohio‑based AI‑enabled data‑center facility, which has already generated $54 million in new orders. Industry analysts have yet to fully incorporate the potential of servicing large hyperscaler clients—companies that drive massive demand for high‑performance computing infrastructure. If PPIH secures these contracts, its revenue base could expand dramatically, outpacing the modest growth forecasts currently modeled.

The dual narratives underscore a broader shift: specialty pharmaceuticals and industrial infrastructure firms are both leveraging niche market penetration and emerging technology trends to unlock outsized growth. Investors should monitor formulary adoption rates for GRAFAPEX and the pipeline of AI‑data‑center contracts for PPIH, as both metrics will likely dictate whether the market re‑prices these stocks. While execution risk remains—particularly around manufacturing scale‑up for Medexus and backlog conversion for PPIH—the upside potential appears significant, making both companies compelling candidates for a growth‑oriented portfolio.